Business Context and Reporting Period
This Form 8-K filing by Dare Bioscience, Inc. (DARE) is dated July 19, 2023. The report addresses a regulatory notice received from the Nasdaq Stock Market regarding the company's compliance with continued listing standards.
Key Financial Metrics
The filing does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity. The only quantitative metric disclosed is the stock price performance: the closing bid price for Dare's common stock was below the minimum $1.00 per share requirement for the last 30 consecutive business days prior to July 19, 2023.
Material Changes
The material event reported is the failure to satisfy Nasdaq Listing Rule 5550(a)(2) due to the sustained low stock price. This is a change in the company's regulatory standing rather than a change in operational financial performance.
Outlook, Risks, and Contingencies
- Compliance Period: Dare has been granted an initial 180-day period (until January 16, 2024) to regain compliance.
- Compliance Criteria: To close the matter, the closing bid price must be at least $1.00 for a minimum of 10 consecutive business days during the compliance period.
- Delisting Risk: If compliance is not achieved by the deadline, the company may be eligible for an additional 180-day period if it meets other listing standards and notifies Nasdaq of its intent to cure the deficiency, potentially via a reverse stock split. Failure to cure or qualify for an extension could result in delisting.
- Appeal Rights: Dare retains the right to appeal a delisting determination to a Nasdaq Hearing Panel.
- Management Commentary: Management stated they will monitor the stock price and consider options to regain compliance, but noted there is no assurance that compliance will be achieved.
Investor Verification Checklist
- Verify the current closing bid price of DARE stock to assess proximity to the $1.00 threshold.
- Monitor for any announcements regarding a reverse stock split or other capital structure changes intended to address the price deficiency.
- Track the company's progress toward the January 16, 2024 compliance deadline.
- Review subsequent filings for any updates on the Nasdaq Staff's discretion regarding the 10-day compliance window or extension eligibility.